Email this article Impact of sibutramine (meridia) on body composition, peptide YY3-36 and serotonin levels in patients with exogenous constitutional obesity
- Authors: Vlasova Y.Y.1, Ametov AS1
-
Affiliations:
- Russian Medical Academy of Postgraduate Education, Federal Agency for Health Care and Social Development
- Issue: Vol 82, No 8 (2010)
- Pages: 44-47
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30639
- ID: 30639
Cite item
Full Text
Abstract
Aim. To evaluate the impact of gradual weight loss and the positive effect of sibutramine on metabolic parameters and the levels of serotonin and neuropeptide YY3-36 levels in patients with exogenous constitutional obesity (ECO).
Subjects and methods. The study included 36 patients (24 women and 12 men; mean age 37.56±0.9 years) with a verified diagnosis of ECO. The height, body weight, waist and hip circumference (WC and HC), and body mass index (BMI) were determined. Adipose tissue content was estimated by a bioimpedance method using an adipose mass analyzer. Serum peptide YY3-36 levels were measured by enzyme immunoassay and blood serotonin concentrations were estimated by high performance liquid chromatography with an electrochemical method.
Results. 12-week sibutramine therapy caused a significant reduction in body weight, WC, HC, and BMI (p < 0.05) in all the patients. At the same time they were found to have a considerable body composition change (total body and visceral fat was decreased, total body water increased, and systemic metabolism was lowered). The mean peptide YY3-36 level was significantly decreased. Sibutramine did not affect the serum content of total serotonin in the sera of patients.
Conclusion. Sibutramine used in the combined therapy in patients with ECO contributes to an effective and steady-state weight loss. Sibutramine treatment causes a reduction in total neuropeptide YY3-36, systemic metabolism, and adipose tissue at the expense of the visceral depot.
Subjects and methods. The study included 36 patients (24 women and 12 men; mean age 37.56±0.9 years) with a verified diagnosis of ECO. The height, body weight, waist and hip circumference (WC and HC), and body mass index (BMI) were determined. Adipose tissue content was estimated by a bioimpedance method using an adipose mass analyzer. Serum peptide YY3-36 levels were measured by enzyme immunoassay and blood serotonin concentrations were estimated by high performance liquid chromatography with an electrochemical method.
Results. 12-week sibutramine therapy caused a significant reduction in body weight, WC, HC, and BMI (p < 0.05) in all the patients. At the same time they were found to have a considerable body composition change (total body and visceral fat was decreased, total body water increased, and systemic metabolism was lowered). The mean peptide YY3-36 level was significantly decreased. Sibutramine did not affect the serum content of total serotonin in the sera of patients.
Conclusion. Sibutramine used in the combined therapy in patients with ECO contributes to an effective and steady-state weight loss. Sibutramine treatment causes a reduction in total neuropeptide YY3-36, systemic metabolism, and adipose tissue at the expense of the visceral depot.
Keywords
About the authors
Yu Yu Vlasova
Russian Medical Academy of Postgraduate Education, Federal Agency for Health Care and Social Development
Email: novorappid@mail.ru
кафедра эндокринологии и диабетологии с курсом эндокринной хирургииканд. мед. наук, докторант; Федеральное агентство по здравоохранению и социальному развитию Государственное образовательное учреждение дополнительного профессионального образования Российская медицинская академия последипломного образования; Russian Medical Academy of Postgraduate Education, Federal Agency for Health Care and Social Development
A S Ametov
Russian Medical Academy of Postgraduate Education, Federal Agency for Health Care and Social Development
Email: Alexander.ametov@gmail.com
кафедра эндокринологии и диабетологии с курсом эндокринной хирургиир мед. наук, проф., зав. каф; Федеральное агентство по здравоохранению и социальному развитию Государственное образовательное учреждение дополнительного профессионального образования Российская медицинская академия последипломного образования; Russian Medical Academy of Postgraduate Education, Federal Agency for Health Care and Social Development
References
- Schwartz M. W., Wood S. C., Porte D. Jr. et al. Central nervous system control of food intake. Nature 2000; 404: 661- 671.
- Konturek P. C., Czenikiewicz-Guzik M., Bielanski W. et al. Neuro-hormonal control of food intake; basic mechanisms and clinical implications. J. Physiol. Pharmacol. 2005; 6: 5-25.
- Sahu A. Minireview: A hypothalamic role in energy balance with special emphasis on leptin. Endocrinology 2004; 145 (6): 2613-2620.
- Пигарева Е. А., Дзеранова Л. К., Рожинская Л. Я. и др. Ожирение и гинекомастия у пациента с центральным несахарным диабетом. Ожирение и метаболизм 2006; 8: 51- 54.
- Schwartz. M. W. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 1996; 45: 531-535.
- Nonogaki K., Strack A., Dallman M. et al. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat. Med. 1998; 4: 1152-1156.
- Calapai G. Leptin increases serotonin turnover by inhibition of brain nitric oxide synthesis. J. Clin. Invest. 1999; 104: 975- 982.
- Пальцев М. А., Кветной И. М. Руководство по нейроиммунологии. М.: Медицина; 2006.
- Viardot A., Heilbronn L. K., Herzog H. et al. Abnormal postprandial PYY response in insulin sensitive nondiabetic subject with a strong family history of type 2 diabetes. Int. J. Obes. 2008; 32: 943-948.
- Бутрова С. А. Сибутрамин (меридиа) в лечении ожирения: опыт применения в России. Клин. фармакол. и тер. 2001 10 (2): 70-75.
- Сметник В. П., Чернуха Г. Е., Валуева Л. Г. Применение сибутрамина (меридиа) у больных с ожирением и нарушением функции яичников. Пробл. репрод. 2002; 1: 10-15.
- Finer N. Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti-obesity agents on cardiovascular risk factors. J. Eur. Heart 2005; 7: 32-38.
- Hainer V., Kabrnova K., Aldhoon B. et al. Serotonin and norepinephrine reuptake inhibition and eating behavior. Ann. N. Y. Acad. Sci. 2006; 1083 (1): 252-269.
- Luquy C. A., Rey J. A. The discovery and status of sibutramine as an anti-obesity drug. Eur. J. Pharmacol. 2002; 440: 119- 128.
- Phelan S., Wadden T. F. Combining behavior and pharmacological treatments for obesity. Obesity 2002; 10 (6): 560-574.
- Bray G. A., Blackburn G. L., Ferguson J. M. et al. Sibutramine produces dose-related weight loss. Obes. Res. 1999; 7: 189- 198.
- Bray G., Ryan D., Gordon D. et al. A double-blind randomized placebo-contolled trial of sibutramine. Obes. Res.. 1996; 4 (3): 263-270.
- Wood S. C., Seeley R. J. Understanding the physiology of obesity: review of recent developments in obesity research. Int. J. Obes. Relat. Metab. 2002; 26: 8-10.
Supplementary files
